Navigation Links
Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
Date:12/4/2008

SEATTLE, Dec. 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that a single institutional investor shall purchase, for $32.65 million, newly issued 10% Convertible Senior Notes due 2011 (the "Notes"), with a conversion price of $0.137 per share.

The new Notes would have a $32.65 million initial principal balance and feature a make-whole provision entitling the holder, upon any conversion of the Notes, to receive the interest payable through scheduled maturity, less any interest paid before conversion.

The Company has also agreed to repurchase from the investor, for approximately $29 million, approximately $30 million aggregate principal amount of outstanding 15% Convertible Senior Notes, Series B 18.33% Convertible Senior Notes and 9.66% Convertible Senior Notes (collectively, the "Repurchased Notes") that were issued in June, August and October 2008, respectively. For such repurchase, the Company will use approximately $16.4 million of the proceeds from the offering of the new Notes, plus funds to be released to the Company from the escrow account that was established to pay the make-whole and interest payments on the Repurchased Notes. Warrants to purchase approximately 5.15 million shares of common stock which are held by the investor are also being surrendered to the Company and will be cancelled. The Company expects to receive net proceeds of approximately $16.3 million from the new Notes (before payment of fees and expenses), after the repurchase of the Repurchased Notes and prior to depositing approximately $9.8 million in escrow for the new Notes' make-whole provision. The new Notes will rank equal in right of payment with all existing and future unsecured senior indebtedness of the Company.

In addition, the Company obtained a conditional put option to require the investor to purchase up to $6 million of its Series C 10% Co
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 DNA vaccine pioneer Immunomic ... development of JRC-LAMP-vax, an innovative and safe potential treatment ... studies began this month in Hawaii, moving the world ... The Japanese red cedar releases pollen that causes devastating ... Cedar pollen wreaks similar havoc in Colorado, New Mexico ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4
... Experience In Molecular DiagnosticsSALT LAKE CITY, Feb. 24 ... care through the development of molecular diagnostic technologies, ... joined the executive management team as the company,s ... Macina will report directly to Kenneth Ward, M.D., ...
... 23 Smith & Nephew, Inc.,(NYSE: SNN ... the,introduction of VISIONAIRE Patient Matched instrumentation for use in ... that,uses a patient,s MRI and x-rays to create custom ... of high performance knee implants. , ...
... 23 Transgenomic Inc. (OTC Bulletin Board: TBIO) is canceling the following Webcast: , ... Quarter 2008 Earnings Release, ... When: Wednesday, February 25, 2009 @ 5:00 p.m. Eastern, ... , , , Transgenomic will communicate by Press Release as soon ...
Cached Biology Technology:Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/22/2014)... 2015, American consumers will finally be able to purchase ... touted as zero-emissions vehicles, most of the cars will ... fuel that contributes to global warming. , Now scientists ... that uses an ordinary AAA battery to produce hydrogen ... current through two electrodes that split liquid water into ...
(Date:8/21/2014)... scientists including researchers from the University of Georgia recently published ... the journal Science . Their discovery paves the way ... in farming and industry. , Canola is grown across ... crop is increasingly cultivated in Georgia. Canola oil used for ... fat and rich supply of omega-3 fatty acids, but the ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Canola genome sequence reveals evolutionary 'love triangle' 2
... backdrop of some of the world,s most sophisticated biological research ... to his colleagues in Congress: immediately upon their return from ... reverse a recent Federal court decision that has brought embryonic ... Rep. Israel was seconded in his plea by Dr. ...
... Westminster, Colo. (August 27, 2010) Although having a ... factor for cardiovascular disease, researchers are only beginning to ... the development of the disease. Now, a study of ... Prevention Study (KEEPS), suggests that as BMI increases, so ...
... Rare but devastating, eye cancer can strike anyone at ... half of all patients partially blind. But a new ... University of Colorado School of Medicine, may change all that. ... eye can block up to 55 percent of harmful radiation, ...
Cached Biology News:Congressman, CSHL president urge quick action to reverse judicial embryonic stem cell research ban 2Congressman, CSHL president urge quick action to reverse judicial embryonic stem cell research ban 3Body mass index and thrombogenic factors in newly menopausal women 2Body mass index and thrombogenic factors in newly menopausal women 3Researcher finds revolutionary way to treat eye cancer 2
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)...
... terminators, template DNA, primers, salts or other ... have proved critical for both standard and ... work with dye terminator cycle sequencing chemistries ... unique uniformity of the magnetic paeticles guarantees ...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
X-gal,1g...
Biology Products: